Newly patented diagnostic tool for aquaculture pathogen to boost shrimp cultivation


Scientists have developed a handy diagnostic tool that detects an aquaculture pathogen known as the White Spot Syndrome Virus (WSSV). The peptide-based diagnostic tool by scientists of Agharkar Research Institute (ARI), an autonomous institute of the Department of Science and Technology (DST) has been grated patent on 31 March 2022 as an alternative biorecognition element.


Infection caused by the WSSV to the shrimp Penaeus vannamei results in huge loss of crop. This high value super-food is susceptible to a wide range of viral and bacterial pathogens and the probability of occurrence of infections is rather high.  Improved nutrition, probiotics, disease resistance, quality control of water, seed and feed, immuno-stimulants and affordable vaccines play an important role in enhancing the production. Technologies for early and rapid detection of pathogens on the field will help fish and shell-fish farming which provides significant export revenue to the country which is a leading supplier of shrimp to the USA.


To provide a handy, self-use diagnostic for WSSV, Dr Prabir Kulabhusan, Dr Jyutika Rajwade and Dr Kishore Paknikar developed a lateral flow assay using gold nanoparticles for easy visualization of the results. Instead of using poly-/mono-clonal antibodies in assay development, the ARI scientists selected twelve amino acid containing peptides from a phage display library by biopanning. This was a time- and cost-saving approach, eliminating the need for immunization of laboratory animals to obtain the antisera. With the use of peptides, cold-chain requirements for storage are reduced and the assay becomes production friendly.


“Our data indicates high specificity (100%) and sensitivity (96.77%) of the assay, early detection from hemolymph, highly reproducible results with a time-to-result of only 20 minutes,” said Dr Jyutika Rajwade. 


The inventors have published this research in Applied Microbiology & Biotechnology and Journal of Molecular Modelling. ARI PhD student Ms Snehal Jamalpure-Lakka, has presented this idea at the National Bio-Entrepreneurship Conclave (NBEC)-2021 and awarded. She will take this work further for commercialization.


Publications


  • PK Kulabhusan, JM Rajwade, ASS Hameed, KM Paknikar. 2017. Lateral flow assay for rapid detection of white spot syndrome virus (WSSV) using a phage-displayed peptide as bio-recognition probe. Applied Microbiology and Biotechnology. 101:4459–4469
  • S Jamalpure, G Panditrao, PK Kulabhusan, AS Sahul Hameed, KM Paknikar, M Joshi, JM Rajwade. 2020. In silico studies on the interaction of phage displayed biorecognition element (TFQAFDLSPFPS) with the structural protein VP28 of White spot syndrome virus. Journal of Molecular Modelling. 26:264 10.1007/s00894-020-04524-z
  • Immunoassay, peptide-based agent and field-usable kit for early rapid detection of white spot syndrome virus (Patent No. 393879)








Handy assay for detection of WSSV


(High specificity for WSSV, other viruses not detected)

In-silico study of VP28 (major capsid protein of WSSV) binding to the 12-mer peptide (blue)




Patent


Description: C:Usersgurudatta.waghDownloadsari-patent-wssv.jpg




*****


SNC / RR




(Release ID: 1816085)
Visitor Counter : 451




Read this release in:



Hindi







Canada – Patented Medicine Prices Review Board Imposes Deadline for Motions for Leave to Intervene in the Redetermination of Board Decisions Regarding the Excessive Pricing of Soliris Dated September 27 and November 8, 2017

The Patented Medicine Prices Review Board will hold a public rehearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc., the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada.

April 1, 2022 – Ottawa, ON – Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board will hold a public rehearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc., the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada. Further details on the public rehearing will be announced at a later date.

Those wishing to participate as an intervener in this proceeding must file with the Board a motion for leave to intervene no later than May 1, 2022. In addition to the requirements for motions for leave to intervene prescribed by section 20 of the Patented Medicine Prices Review Board Rules of Practice and Procedure, SOR/2012-247, the Board directs proposed interveners to indicate in their motion materials whether they intend to seek leave to introduce evidence in the redetermination.

The Panel has tentatively scheduled any motions for leave to intervene in this matter to be heard on June 20 and/or 21, 2022.

For further information on the process for seeking leave to intervene, please contact:

Sherri Wilson

Director / Directrice

Board Secretariat / Secrétariat du Conseil

Patented Medicine Prices Review Board / Conseil d’examen du prix des médicaments brevetés

Government of Canada / Gouvernement du Canada

Email: sherri.wilson@pmprb-cepmb.gc.ca

Canada – Patented Medicine Prices Review Board seeks applicants for Chairperson position

Ottawa, ON — Patented Medicine Prices Review Board

The Government of Canada is seeking applicants for the Chairperson position on the Patented Medicine Prices Review Board by way of an open, transparent, and merit-based Governor in Council selection process.

Members of the Board are part-time, Governor in Council appointees who preside over hearings into allegations of excessive drug pricing brought by PMPRB staff against patent-holding pharmaceutical companies.

The Chairperson exercises direction, as Chief Executive Officer, over the quasi-judicial and operational functions of the PMPRB and exercises authority as Deputy Head under the Financial Administration Act.

Candidates interested in this unique opportunity are encouraged to apply online by visiting Canada.ca for more information.